par Xenophontos, Eleni;Giaj-Levra, Niccolò;Durieux, Valérie 
;van Geffen, Wouter W.H.;Grisay, Guillaume;De la Pinta Alonso, C;Arasanz, Hugo;Prisciandaro, Elena;Ferrara, Roberto;Derks, J;von der Thüsen, Jan;Dickhoff, Chris;Brandão, Mariana ;Faivre-Finn, Corinne;Edwards, John;de Ruysscher, Dirk;Remon, Jordi;Dingemans, Anne Marie A.M.C.;Berghmans, Thierry
Référence Lung cancer, 207, page (108671)
Publication Publié, 2025-07-01
;van Geffen, Wouter W.H.;Grisay, Guillaume;De la Pinta Alonso, C;Arasanz, Hugo;Prisciandaro, Elena;Ferrara, Roberto;Derks, J;von der Thüsen, Jan;Dickhoff, Chris;Brandão, Mariana ;Faivre-Finn, Corinne;Edwards, John;de Ruysscher, Dirk;Remon, Jordi;Dingemans, Anne Marie A.M.C.;Berghmans, Thierry Référence Lung cancer, 207, page (108671)
Publication Publié, 2025-07-01
Article révisé par les pairs
| Résumé : | Stage III non-small cell lung cancer (NSCLC) is a heterogenous disease requiring a multimodality treatment approach. For resectable stage III NSCLC, treatments incorporating surgery might be beneficial, however, a definition on resectable disease is lacking. The European Organization for the Treatment and Research of Cancer (EORTC) Lung Cancer Group initiative aims to provide a uniform definition of resectable stage III NSCLC. As part of this initiative, we conducted a systematic review to identify definitions on resectability; the medical specialties involved for making the decision and the required work-up aiding the decision. |
